

# Supplementary File S5

## Clinical Decision Flowchart

Step-by-Step Visual Guide for LAI-PrEP Bridge Period Navigation

Adrian C. Demidont and Kandis Backus

*Viruses* Journal Supplementary Materials

### Purpose of This Flowchart

This clinical decision flowchart provides systematic guidance for LAI-PrEP bridge period management at the point of prescription. It translates the evidence-based decision support algorithm into actionable clinical workflows, enabling clinicians to:

- Rapidly identify patients for same-day switching protocols
- Assess population-specific risks and barriers
- Stratify patients by predicted success rate
- Select appropriate evidence-based interventions
- Implement structured follow-up protocols

**Critical Insight:** Without systematic intervention, 47% of LAI-PrEP prescriptions do not result in injection initiation. This flowchart addresses that implementation gap.

### 1 Step 1: Oral PrEP Status Assessment

#### INITIAL TRIAGE QUESTION

**Is the patient currently taking oral PrEP?**

This is the single most important clinical decision point that determines bridge period pathway.

#### 1.1 YES: Patient on Oral PrEP → Expedited Pathway

## Secondary Question: Recent HIV Test?

### 1.1.1 If YES (HIV test within 7 days):

#### \* PRIORITY 1: Same-Day Switching Protocol

**Predicted Success: 90%**

**Bridge Period: 0–3 days**

**Actions at Prescription Visit:**

- ✓ Inject TODAY (preferred) or within 3 days maximum
- ✓ Submit insurance authorization same day
- ✓ Document switch in medical record
- ✓ Schedule next injection (2 or 6 months)
- ✓ Provide injection site care instructions

**Evidence:** OPERA cohort (n=302), Trio Health (n=146) demonstrated 85–90% success with same-day protocols.

**Key Point:** Do NOT make these patients wait. They are already engaged and adherent.

### 1.1.2 If NO (HIV test $\geq$ 7 days ago or never):

#### \* PRIORITY 2: Rapid Transition Protocol

**Predicted Success: 85–90%**

**Bridge Period: 7–14 days**

**Actions at Prescription Visit:**

- ✓ Order STAT HIV testing (same day if possible)
- ✓ Submit insurance authorization TODAY (do not wait for test)
- ✓ Schedule injection for next week (tentative)
- ✓ Confirm injection once negative test result received
- ✓ Continue oral PrEP until injection
- ✓ Set text reminders for test and injection appointments

**Goal:** Minimize wait time to preserve oral PrEP adherence momentum.

## 1.2 NO: Patient NOT on Oral PrEP â†’ Standard Pathway

Proceed to **STEP 2: Population & Barrier Assessment**

This pathway requires systematic risk assessment and intervention planning.

## 2 Step 2: Population & Barrier Assessment

### 2.1 Population Identification

Identify patient's primary population (baseline success rate without barriers):

Population	Baseline Success	Evidence Source
MSM	55%	HPTN 083
Cisgender Women	45%	HPTN 084, PURPOSE-1
Transgender Women	50%	HPTN 083, PURPOSE-2
Adolescents (16–24)	35%	PURPOSE-1, oral PrEP
PWID	25%	Oral PrEP cascade
Pregnant/Lactating	45%	PURPOSE-1
General Population	53%	Real-world cohorts

### 2.2 Barrier Assessment Checklist

Check ALL barriers that apply. Each barrier reduces success rate by approximately 10 percentage points:

#### Structural Barriers:

- ☐ Transportation barriers (no reliable access to clinic)
- ☐ Childcare needs (cannot attend appointments without childcare)
- ☐ Housing instability (homeless or unstable housing)
- ☐ Insurance delays expected (prior authorization typically >2 weeks)
- ☐ Scheduling conflicts (work/school during clinic hours)

#### Interpersonal & Systemic Barriers:

- ☐ Medical mistrust (history of negative healthcare experiences)
- ☐ Privacy concerns (disclosure fears, confidentiality needs)
- ☐ Healthcare discrimination (experienced/anticipated discrimination)
- ☐ Competing priorities (other urgent health/life needs)
- ☐ Limited healthcare navigation experience (new to system)

#### Population-Specific Barriers:

- ☐ Legal/criminalization concerns (PWID, sex work, immigration)
- ☐ Lack of government identification
- ☐ Active substance use (interfering with appointment attendance)

## 2.3 Calculate Adjusted Success Rate

### Calculation Formula

**Adjusted Success Rate = Baseline Rate – (10% ÷ Number of Barriers)**

**Examples:**

- MSM (55%) with 1 barrier (transportation) = 45% success
- Cisgender woman (45%) with 3 barriers (transport, childcare, mistrust) = 15% success
- PWID (25%) with 4 barriers = Cannot go below 0% (use 5–10% estimate)

**Note:** This is a simplified clinical calculation. The full algorithm uses multiplicative probability adjustments for greater precision.

## 3 Step 3: Risk Categorization & Intervention Selection

Based on adjusted success rate, categorize patient and select interventions:

### 3.1 Low Risk: Adjusted Success ≥70%

**Risk Level:** Low

**Predicted Success:** 70–85%

**Standard Protocols:**

- Text/email reminders for appointments
- Expedited HIV testing (within 3–5 days)
- Standard insurance authorization process
- Patient education materials

**Follow-up:** Brief check-in call 1 week post-prescription

### 3.2 Moderate Risk: Adjusted Success 50–69%

**Risk Level:** Moderate

**Predicted Success:** 60–75% (with interventions)

**Enhanced Protocols:**

- **Assign patient navigator** (2–3 contacts during bridge period)
- Text/email/phone reminders
- Expedited/same-day HIV testing
- Address 1–2 key barriers with targeted interventions
- Insurance support (tracking, appeals if needed)

**Barrier-Specific Interventions:**

- Transportation – Uber/Lyft vouchers, mileage reimbursement
- Scheduling – Extended hours, weekend appointments
- Insurance – Pre-authorization assistance, patient assistance programs

**Follow-up:** Navigator contact within 24–48 hours, then weekly

### 3.3 High Risk: Adjusted Success 30–49%

**Risk Level:** High

**Predicted Success:** 40–60% (with intensive interventions)

**Intensive Interventions Required:**

- **Navigator assignment** (MANDATORY – minimum 3 contacts)
- Accelerated HIV testing (same-day rapid test if possible)
- Transportation support (vouchers, rides, mileage)
- Barrier-specific intensive support:
  - Childcare vouchers or on-site childcare
  - Flexible scheduling (early/late/weekend)
  - Insurance advocacy and appeals
  - Peer navigation (if available)
- Close follow-up (every 2–3 days)
- Case conference if barriers persist

**Multiple Intervention Modalities:** Combine structural support (transportation, childcare) with interpersonal support (navigation, peer support)

### 3.4 Very High Risk: Adjusted Success <30%

**Risk Level:** Very High

**Predicted Success:** 20–40% (with maximum interventions)

**Maximum Intensity Interventions:**

- **Intensive navigation** (multiple contacts weekly)
- **Peer navigator** (if available, especially for PWID, transgender populations)
- **Harm reduction integration** (for PWID)
- **Mobile/outreach services** (bring services to patient)
- **Low-barrier protocols:**
  - No ID requirement
  - Flexible scheduling

- Home visits if needed
- Telehealth options

- Address ALL identified barriers simultaneously
- Daily contact first week, then every 2–3 days
- Case management beyond bridge period

**Critical:** These patients require healthcare system-level support, not just individual interventions. Consider alternative care delivery models.

## 4 Step 4: Evidence-Based Intervention Library

Select interventions based on specific barriers and population:

Intervention	Target Barriers/Populations	Effect
<b>High-Impact Interventions (&gt;15% improvement)</b>		
Same-day switching	Oral PrEP patients	+25%
Patient navigation	All barriers, all populations	+15%
Peer navigation	PWID, transgender, MSM	+18%
Harm reduction integration	PWID, substance use	+18%
<b>Moderate-Impact Interventions (10–15%)</b>		
Transportation support	Transportation barriers	+12%
Accelerated testing	HIV testing delays	+12%
Anti-discrimination protocols	Discrimination experiences	+12%
Low-barrier protocols	Multiple barriers, PWID	+12%
Childcare support	Childcare needs	+10%
Insurance support	Insurance delays	+10%
Prenatal integration	Pregnant/lactating	+10%
Medical mistrust intervention	Medical mistrust	+10%
<b>Supportive Interventions (5–10%)</b>		
Flexible scheduling	Scheduling conflicts	+6%
Text/email reminders	All patients	+8%
Confidentiality protections	Privacy concerns, adolescents	+8%
Pregnancy counseling	Pregnant/lactating	+8%
Mobile delivery	Housing instability, PWID	+8%
Cultural competency	Discrimination, mistrust	+7%
Telehealth options	Transportation, rural	+5%
Community partnerships	All populations	+5%
Extended clinic hours	Scheduling conflicts	+5%
Same-day appointments	Competing priorities	+5%

## 5 Step 5: Special Population Protocols

## 5.1 PWID Fast Track

### People Who Inject Drugs: Alternative Care Model Required

**Critical Insight:** Traditional clinic-based care results in <10% success for PWID. An alternative approach is essential.

**Required Elements:**

- **MUST** partner with syringe services program (SSP) or harm reduction program
- Bring ALL services to the patient (co-locate at SSP site)
- Use peer navigators with lived experience
- Low-barrier protocols:
  - No government ID required
  - No abstinence requirements
  - Flexible appointment times
  - No-show tolerant (immediate rescheduling)
- Rapid HIV testing at SSP site (same-day results)
- Mobile delivery if SSP partnership unavailable
- Integrate with medication-assisted treatment (MAT)
- Address housing and food insecurity simultaneously

**Expected Outcome:** 30–40% success (compared to <10% in traditional clinic)

**Evidence:** Harm reduction PrEP literature, oral PrEP PWID cascade studies

## 5.2 Adolescent Fast Track

### Adolescents (16–24): Youth-Specific Approach

**Key Barriers:** Transportation dependence, privacy concerns, limited healthcare navigation experience

**Required Elements:**

- Youth-specific navigator (ESSENTIAL – trained in adolescent development)
- Transportation without parental involvement (vouchers, youth-friendly transit)
- Confidential scheduling and communication
- School-friendly appointment times (after school, early morning, weekends)
- Bundle appointments (test + inject same day when possible)
- Text-based communication (preferred by adolescents)
- Privacy protections (manage insurance EOBs, parental notifications)
- Brief, focused visits (adolescent attention span)

**Expected Outcome:** 35–50% success with navigation (vs. <20% without)  
**Evidence:** PURPOSE-1 adolescent cohort, oral PrEP adolescent cascade

### 5.3 Oral PrEP Patients: Your Easiest Win

#### Current Oral PrEP Users: Highest Success Opportunity

**Critical Message:** These are your highest-success patients. Do NOT let them fall through cracks.  
**Streamlined Protocol:**

- Recent HIV test (within 7 days)? â†’ INJECT TODAY
- No recent test? â†’ Order test, inject within 7 days maximum
- Same-day insurance authorization (do not delay)
- Minimal wait time (preserve adherence momentum)
- Build on existing provider relationship
- Continue oral PrEP until injection (if needed)

**Expected Outcome:** 85–90% success

**Key Point:** Every day of delay increases risk of oral PrEP discontinuation and loss to follow-up.

## 6 Step 6: Implementation & Follow-Up Timeline

### 6.1 Day 0: Prescription Visit



**Essential Actions at Prescription:**

- ☐ Complete barrier assessment (use checklist in Step 2)
- ☐ Calculate adjusted success rate and risk category
- ☐ Select interventions based on this flowchart
- ☐ Order HIV testing (expedited/STAT)
- ☐ Submit insurance authorization SAME DAY (critical!)
- ☐ Assign patient navigator if moderate to very high risk
- ☐ Provide transportation voucher if barrier identified
- ☐ Schedule tentative injection appointment
- ☐ Set up text/email reminders
- ☐ Give patient clear timeline and expectations
- ☐ Provide patient handout (Supplementary File S2)
- ☐ Document barriers and intervention plan in medical record

**Time Investment:** 15–20 minutes for comprehensive assessment

## 6.2 Day 1: Next Business Day

**Navigator Actions:**

- ☐ Contact patient (phone or text)
- ☐ Confirm understanding and motivation
- ☐ Address any new barriers that have emerged
- ☐ Confirm all appointment times
- ☐ Check insurance authorization status
- ☐ Problem-solve any concerns

## 6.3 Days 2–7: Testing Phase

**Critical Period:**

- ☐ HIV testing completed (ideally within 3–5 days)
- ☐ Results reviewed same day or next business day
- ☐ Navigator provides results and confirms injection appointment
- ☐ Text reminders sent (48 hours and 24 hours before injection)
- ☐ Insurance authorization confirmed or escalated if denied

- ☐ Address any barriers to injection appointment

**High-Risk Patients:** Contact every 2–3 days during this period

## 6.4 Days 7–28: Injection Window

### TARGET: FIRST INJECTION

#### Injection Visit:

- ☐ Administer first injection
- ☐ Patient education on injection-site reactions (common, self-limited)
- ☐ Provide contact information for questions/concerns
- ☐ Schedule next injection appointment (2 months for cabotegravir, 6 months for lenacapavir)
- ☐ Hand off to retention/persistence program
- ☐ Document outcome in tracking system
- ☐ Celebrate success with patient!

#### Goal Timeline:

- Oral PrEP patients: 0–14 days
- New patients, low risk: 14–21 days
- New patients, moderate/high risk: 21–28 days

## 6.5 If Patient Misses Appointment

### SAME-DAY RESPONSE REQUIRED

#### Immediate Actions (Day of Miss):

- Call patient immediately
- Identify barrier that caused missed appointment
- Problem-solve barrier with patient
- Reschedule for ASAP (within 3 days if possible)
- Offer additional support (transportation, flexible timing, etc.)

#### If Cannot Reach:

- Send text message
- Try alternate contact method (email, secondary phone)
- Attempt contact daily for 3 days minimum

- Consider home visit or outreach for very high-risk patients
- Do NOT give up after one attempt

**Key Message:** Missing one appointment is NOT failure. Most patients who miss can still be successfully transitioned with rapid outreach and problem-solving.

## 7 Clinical Pearls

### Top 10 Implementation Insights

- 1. The #1 Thing:** Identify oral PrEP patients and transition them FAST. This is your easiest win and highest success rate.
- 2. The #2 Thing:** Assign a navigator for anyone with 3+ barriers or very high-risk populations. Navigation is the single most effective intervention.
- 3. The #3 Thing:** Submit insurance authorization THE SAME DAY as prescription. Do not wait for HIV test results. Delays here cause 10–15% attrition.
- 4. What NOT to Do:** Prescribe and hope. Without proactive intervention, 47% will not initiate. Passive approaches fail.
- 5. PWID Specific:** Traditional clinic-based care will fail for PWID. You MUST use harm reduction approach with SSP integration. There is no successful traditional alternative.
- 6. Timeline Matters:** Every extra day increases attrition risk. Aim for <14 days for oral PrEP transitions, <28 days for new patients.
- 7. Barrier Assessment is Non-Negotiable:** You cannot select appropriate interventions without knowing barriers. Budget 5 minutes for systematic assessment.
- 8. Multiple Barriers Require Multiple Interventions:** Patients with 3+ barriers need 2–3 interventions simultaneously. Single interventions are insufficient.
- 9. Don't Reinvent the Wheel:** Use evidence-based interventions from the library (Step 4). Effectiveness is proven; customize implementation to your setting.
- 10. Track Outcomes:** Monitor bridge period success rates by population and intervention. Use data to improve your local protocols continuously.

## 8 Evidence Base

This flowchart is based on:

- **Clinical Trials:** HPTN 083 (n=4,566 MSM/transgender women), HPTN 084 (n=3,224 cisgender women), PURPOSE trials (n=10,761 across multiple populations)
- **Real-World Implementation:** CAN Community Health Network (n=302), OPERA cohort, Trio Health, SPAN clinics
- **Barrier Literature:** PrEP cascade studies, implementation science, structural barrier research
- **Intervention Evidence:** Systematic reviews and meta-analyses of navigation (k=23 RCTs), harm reduction integration, peer support
- **Computational Validation:** Decision support algorithm validated at UNAIDS scale (21.2 million patients), 100% unit test pass rate

## Usage Instructions

### For Clinicians:

- Print this flowchart and keep in LAI-PrEP prescription area
- Use at EVERY LAI-PrEP prescription to systematically assess and intervene
- Document selected interventions in medical record
- Share with nursing staff and navigators for care coordination

### For Clinic Administrators:

- Train all prescribers on flowchart use
- Ensure navigation resources available for moderate/high-risk patients
- Track bridge period outcomes by population and risk level
- Use data to refine local protocols and resource allocation

### For Researchers:

- Test flowchart effectiveness in prospective implementation studies
- Validate risk stratification accuracy in diverse settings
- Evaluate cost-effectiveness of tiered intervention approach
- Document adaptations needed for specific contexts

*Use this flowchart at every LAI-PrEP prescription to systematically identify risks and implement evidence-based interventions.*

*Based on: Demidont, A.C.; Backus, K.V. Bridging the Gap: Computational Validation of Clinical Decision Support Algorithm for Long-Acting Injectable PrEP Bridge Period Navigation. Viruses 2025.*